Tesamorelin powder has been shown to reduce lipodystrophy in HIV-infected individuals.
Lipodystrophy is a condition that causes changes in placement of body
fat, including wasting and fat accumulation, and changes in metabolism.
Similar to Tesamorelin is Sermorelin, which may be taken with GHRP-6 is
clinical trials, that also promotes production and possible fat loss.
Individuals with lipodystrophy may develop excess fat most notably
around the liver, stomach, and other abdominal organs (visceral body
Tesamorelin, (formerly known as TH9507), is a type of peptide called a hormone-releasing factor (GHRF). GHRF causes hormone to be created
and spread in the body, which helps increase metabolism, reduce belly
fat, improve body shape, and use of energy. Tesamorelin (formerly known
as TH9507) is a synthetic grow hormone-releasing factor that stimulates
the pituitary gland in the brain to secrete hormone; this indirect
approach appears to maintain more stable, natural levels, like CJC-1295
DAC,. Clinical trials have shown that tesamorelin significantly reduces
abdominal fat with fewer side effects than human grow hormone itself,
although abdominal fat may return after the Tesamorlein is discontinued
(depending upon the individual). Tesamorelin has been shown to reduce
lipodystrophy in HIV-infected individuals as well as similarly reducing
abdominal fat in NON-HIV-Infected individuals.
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a trans-3-Hexenoic acid group.Tesamorelin
(also known as Egrifta) is a synthetic form of growth-hormone-releasing
hormone which is used in the treatment of HIV-associated
lipodystrophy.tendon fibroblasts in a dose-dependent manner as revealed
by transwell filter migration assay. BPC 157 also dose dependently
accelerated the spreading of tendon fibroblasts on culture dishes. The
F-actin formation as detected by FITC-phalloidin staining was induced in
BPC 157-treated fibroblasts. The protein expression and activation of
FAK and paxillin were determined by Western blot analysis, and the
phosphorylation levels of both FAK and paxillin were dose dependently
increased by BPC 157 while the total amounts of protein was unaltered.
In conclusion, BPC 157 promotes the ex vivo outgrowth of tendon
fibroblasts from tendon explants, cell survival under stress, and the in
vitro migration of tendon fibroblasts, which is likely mediated by the
activation of the FAK-paxillin pathway.
1. Triptorelin raises test levels by causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins
luteinizing hormone (LH) and follicle stimulating hormone (FSH).
2. Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or
breast cancer, precocious puberty,estrogen-dependent conditions (such as
endometriosis or uterine fibroids), and in assisted reproduction.